CI Financial Announces Filing and Mailing of Circular for Special Meeting to Approve Plan of Arrangement with Mubadala Capital ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...

On Wednesday, New York-headquartered Focus Financial Partners announced plans to make Cardinal Point, which it acquired in ...

The deal counter is buzzing with new funding rounds across sectors. This and more in todays ETtech Morning Dispatch.

New U.S. Senator Jim Justice has earned a reputation for dodging fines, ignoring court orders, breaking contracts, and paying ...

U.S. law firm Skadden, Arps, Slate, Meagher & Flom on Thursday said it has opened an office in Abu Dhabi, following other ...

Healthcare-focused SaaS firm Innovaccer Inc. has secured $275 million in funding from investors including B Capital Group and ...

Tiger Global-backed Innovacer, healthcare-focused software-as-a-service startup (SaaS), has secured $275 million in a ...

The last round in 2021 valued the healthcare technology firm at $3.2 billion, more than doubling its valuation from $1.3 ...

Defiant is a new early-stage VC firm focused on B2B SaaS and fintech coming out of stealth Thursday. Joseph Pizzolato ...

Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, announced a multi-target collaboration with Novartis to identify and develop potentially first-in-class ...